Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

Micafungin Breakthrough Fungemia in Patients with Hematological Disorders

Muneyoshi Kimura, Hideki Araoka, Hisashi Yamamoto, Shigeki Nakamura, Minoru Nagi, Satoshi Yamagoe, Yoshitsugu Miyazaki, Sho Ogura, Takashi Mitsuki, Mitsuhiro Yuasa, Daisuke Kaji, Kosei Kageyama, Aya Nishida, Yuki Taya, Hiroshi Shimazu, Kazuya Ishiwata, Shinsuke Takagi, Go Yamamoto, Yuki Asano-Mori, Naoyuki Uchida, Atsushi Wake, Shuichi Taniguchi, Akiko Yoneyama
Muneyoshi Kimura
aDepartment of Infectious Diseases, Toranomon Hospital, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hideki Araoka
aDepartment of Infectious Diseases, Toranomon Hospital, Tokyo, Japan
eOkinaka Memorial Institute for Medical Research, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hisashi Yamamoto
bDepartment of Hematology, Toranomon Hospital, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shigeki Nakamura
cDepartment of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Minoru Nagi
cDepartment of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satoshi Yamagoe
cDepartment of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshitsugu Miyazaki
cDepartment of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sho Ogura
aDepartment of Infectious Diseases, Toranomon Hospital, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takashi Mitsuki
dDepartment of Hematology, Toranomon Hospital Kajigaya, Kanagawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mitsuhiro Yuasa
bDepartment of Hematology, Toranomon Hospital, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daisuke Kaji
bDepartment of Hematology, Toranomon Hospital, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kosei Kageyama
bDepartment of Hematology, Toranomon Hospital, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aya Nishida
bDepartment of Hematology, Toranomon Hospital, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuki Taya
dDepartment of Hematology, Toranomon Hospital Kajigaya, Kanagawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroshi Shimazu
bDepartment of Hematology, Toranomon Hospital, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazuya Ishiwata
dDepartment of Hematology, Toranomon Hospital Kajigaya, Kanagawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shinsuke Takagi
bDepartment of Hematology, Toranomon Hospital, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Go Yamamoto
bDepartment of Hematology, Toranomon Hospital, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuki Asano-Mori
bDepartment of Hematology, Toranomon Hospital, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naoyuki Uchida
bDepartment of Hematology, Toranomon Hospital, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Atsushi Wake
dDepartment of Hematology, Toranomon Hospital Kajigaya, Kanagawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shuichi Taniguchi
bDepartment of Hematology, Toranomon Hospital, Tokyo, Japan
eOkinaka Memorial Institute for Medical Research, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akiko Yoneyama
aDepartment of Infectious Diseases, Toranomon Hospital, Tokyo, Japan
eOkinaka Memorial Institute for Medical Research, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.02183-17
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Limited data are available on micafungin breakthrough fungemia (MBF), fungemia that develops on administration of micafungin, in patients with hematological disorders. We reviewed medical and microbiological records of patients with hematological disorders who developed MBF between January 2008 and June 2015. A total of 39 patients with MBF were identified, and Candida (30 strains) and non-Candida (9 strains) fungal species were recognized as causative strains. Among 35 stored strains, Candida parapsilosis (14 strains), Trichosporon asahii (7 strains), Candida glabrata (5 strains), and other fungal species (9 strains) were identified by sequencing. Neutropenia was identified as an independent predictor of non-Candida fungemia (P = 0.023). T. asahii was the most common causative strain (7/19) during neutropenia. The 14-day crude mortality rate of patients treated with early micafungin change (EMC) to other antifungal agents was lower than that of the patients not treated with EMC (14% versus 43%, P = 0.044). Most of the stored causative Candida strains were susceptible (80%) or showed wild-type susceptibility (72%) to micafungin. The MICs of voriconazole for T. asahii were low (range, 0.015 to 0.12 μg/ml), whereas the MICs of amphotericin B for T. asahii were high (range, 2 to 4 μg/ml). MBF caused by non-Candida fungus should be considered, especially in patients with neutropenia. EMC could improve early mortality. Based on epidemiology and drug susceptibility profiling, empirical voriconazole-containing therapy might be suitable for treating MBF during neutropenia to cover for T. asahii.

INTRODUCTION

Fungemia, mostly due to Candida spp., rarely occurs in patients with cancer and hematological malignancies but is associated with substantial mortality (1). Recently, breakthrough fungemia, which develops upon administration of antifungal agents (AFAs), has been increasingly recognized in patients with hematological disorders (2–4). Previous studies reported that the distribution of causative fungal species depends on the AFA administered when breakthrough fungemia develops (2). However, studies of breakthrough fungemia during administration of echinocandins, including micafungin, are rare, although echinocandin prophylaxis and empirical echinocandin administration have been approved as current clinical practices for high-risk patients with hematological diseases (5–8). Thus, we conducted this study, which focused on micafungin breakthrough fungemia (MBF), to clarify the characteristic features and determine the appropriate therapeutic strategy.

(This work was presented in part at ID Week 2017, San Diego, CA, 4 to 8 October 2017.)

RESULTS

Clinical presentation and characteristics of patients with MBF.A total of 39 patients with MBF were identified during the study period. Of the 39 patients, 36 received ≥150 mg/day of micafungin when MBF developed. Clinical characteristics of patients with MBF are shown in Table 1. The median duration of micafungin exposure prior to breakthrough was 40 days (range, 4 to 137 days). The most common underlying hematological disorder was acute myeloid leukemia. Nineteen patients developed MBF in the presence of neutropenia. Additionally, 9 patients developed catheter-related fungemia, and all had candidemia. Among the 34 patients who were treated with an empirical AFA, 27 patients received liposomal amphotericin B (69%); 14-day and 30-day crude mortality rates were 33% and 46%, respectively.

View this table:
  • View inline
  • View popup
TABLE 1

Clinical characteristics of 39 patients with MBF

Causative fungal species of MBF.Among the 39 causative fungal strains, 9 were non-Candida strains. The 35 causative fungal strains that were stored and identified by sequencing were Candida parapsilosis (14 strains), Trichosporon asahii (7 strains), Candida glabrata (5 strains), Candida albicans (3 strains), Candida guilliermondii (2 strains), Candida krusei (1 strain), Candida fermentati (1 strain), Cryptococcus neoformans (1 strain), and Fusarium dimerum species complex (1 strain). The remaining 4 nonstored strains were identified only using Vitek or VITEK2 as C. parapsilosis (2 strains), C. krusei (1 strain), and Candida tropicalis (1 strain).

Differences between candidemia and non-Candida fungemia.Univariate analysis revealed that the proportion of patients who developed non-Candida fungemia in the presence of neutropenia was higher than that of patients who developed candidemia in the presence of neutropenia (P = 0.008) (Table 2). Additionally, neutropenia was identified as an independent predictor of non-Candida fungemia among MBF patients in multivariate analysis (adjusted odds ratio, 13.8; 95% confidence interval, 1.44 to 132).

View this table:
  • View inline
  • View popup
TABLE 2

Differences between patients with candidemia and patients with fungemia other than candidemiaa

Distribution of causative fungal species in the presence of neutropenia (absolute neutrophil count [ANC] ≤ 500/μl) and nonneutropenia (ANC > 500/μl).T. asahii was the most common causative strain (37%) in patients with neutropenia (Table 3). However, 19 of the 20 causative fungal strains (95%) in nonneutropenic patients were Candida strains (95%).

View this table:
  • View inline
  • View popup
TABLE 3

Distribution of causative MBF species during neutropenia and nonneutropeniaa

Microbiological characteristics of MBF.The microbiological characteristics of the 35 fungal strains stored for sequencing-based identification and antifungal drug susceptibility were determined. The remaining 4 nonstored strains were excluded.

(i) Non-Candida strains.Nine patients had fungemia caused by non-Candida fungal strains. All 9 causative fungal strains were stored and analyzed (Table 4, patients 1 to 9) and were properly identified by using matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS). All 9 strains had a micafungin MIC of >16 μg/ml. MICs of voriconazole and amphotericin B for all 7 T. asahii strains were 0.015 to 0.12 μg/ml and 2 to 4 μg/ml, respectively. Other susceptibility results are shown in Table 4.

View this table:
  • View inline
  • View popup
TABLE 4

Microbiological characteristics of MBFa

(ii) Candida strains.In total, 26 of the 30 Candida strains that caused MBF were stored and analyzed (Table 4), and 24 of the 26 (92%) were accurately identified with MALDI-TOF MS. However, C. fermentati was not identified, and a C. parapsilosis strain was misidentified as Candida metapsilosis by MALDI-TOF MS. The micafungin MICs for all 26 strains ranged from 0.015 to 4 μg/ml. C. fermentati has no established breakpoint, and no epidemiological cutoff value (ECV) for C. fermentati has been established for micafungin. Among the 25 strains for which breakpoints and an ECV were established for micafungin, 18 strains showed wild-type susceptibility to micafungin and 20 strains were susceptible to micafungin. Nevertheless, C. parapsilosis was significantly more frequent in micafungin breakthrough candidemia (MBC) caused by micafungin-susceptible Candida strains (14/20) than in MBC caused by micafungin-nonsusceptible Candida strains (0/5) (P = 0.0087) (see Table S1 in the supplemental material). All 14 C. parapsilosis strains were not resistant to fluconazole and voriconazole (Table 4); no C. glabrata strain was susceptible to fluconazole. Also, 4 of the 5 C. glabrata strains showed non-wild-type susceptibility to voriconazole.

Analysis of risk factors for crude 30-day mortality of MBF.In univariate analysis, an age of ≥60 years, chronic renal failure, and septic shock were significant risk factors for 30-day crude mortality (Table 5). Additionally, mortality in patients with Trichosporon fungemia tended to be higher than that in patients with candidemia (71% versus 41%, P = 0.08).

View this table:
  • View inline
  • View popup
TABLE 5

Risk factor analysis for crude 30-day mortality of MBFa

In multivariate analysis, an age of ≥60 years, chronic renal failure, septic shock, and systemic steroid administration were identified as independent risk factors for mortality (Table 5).

Efficacy of early empirical micafungin change to other antifungal agents.Among the 35 patients who survived for 48 h after the onset of MBF, 21 patients received early micafungin change to other AFA (EMC) treatment. The 14-day crude mortality rate of the EMC group was significantly lower than that of the non-EMC group (Fig. 1) (14% versus 43%, P = 0.044), but baseline characteristics of the two groups did not differ significantly (see Table S2 in the supplemental material). Also, the 30-day crude mortality rate of the EMC group was lower than that of the non-EMC group, but the difference was not significant (33% versus 50%, P = 0.21).

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Fourteen-day crude mortality rates of the EMC group and the non-EMC group. EMC, early micafungin change to other antifungal agents.

DISCUSSION

To the best of our knowledge, this is the first and largest study clarifying the characteristic features of MBF and determining the appropriate therapeutic strategy. The administration of echinocandins, including micafungin, is recommended as empirical and prophylactic AFA administration in some high-risk patients (5–7, 9). However, echinocandin breakthrough fungemia, including MBF, is recognized as a severe infection among patients administered echinocandins (10–13). Thus, it is important to establish the appropriate therapeutic strategy for MBF.

The exact incidence of MBF among patients who receive micafungin administration remains unknown. However, based on our previous study, it is predicted to be low, because only 17 cases with MBC were documented among 768 cases who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) (14). In the present study, most of the Candida species that caused MBC were susceptible or showed wild-type susceptibility to micafungin (Table 4). These results were the same as those of our previous study (14). Furthermore, C. parapsilosis was significantly more frequent in MBC caused by micafungin-susceptible Candida strains than in MBC caused by micafungin-nonsusceptible Candida strains (P = 0.0087) (see Table S1 in the supplemental material); C. parapsilosis was the most common causative Candida species in MBC caused by micafungin-susceptible Candida strains (14/20). These results indicate that the current breakpoint of micafungin for C. parapsilosis established by the Clinical Laboratory and Standards Institute (CLSI) may not be well correlated with prophylactic efficacy of micafungin for C. parapsilosis in patients with high-risk hematological disorders.

In this study, EMC significantly improved the 14-day crude mortality rate (Fig. 1). Among all 39 patients, EMC significantly improved 14-day crude mortality (adjusted hazard ratio, 0.089; 95% confidence interval, 0.0083 to 0.95). A clear understanding of the epidemiology of MBF is essential to determine the appropriate empirical AFA. Table 3 shows the causative fungal strains of MBF. Similar fungal strains, except for the Aspergillus and Mucor species that are rarely cultured from blood samples, were reported to be the causative strains of echinocandin breakthrough invasive fungal infections in some previous reports (11–13). Thus, our data are likely applicable to MBF in other clinical settings. In our study, neutropenia was an independent predictor of fungemia caused by non-Candida fungal strains (Table 2). Neutropenia was also a predictor of T. asahii fungemia in univariate analysis (P = 0.003), and T. asahii was the most common strain causing MBF in patients who developed neutropenia (Table 3). Identifying this kind of predictor is important because most non-Candida fungal species cannot be distinguished from Candida species merely by microscopic appearance after Gram staining of positive blood cultures. A systematic review revealed that 84.8% (67/79) of Trichosporon infections among patients with hematological disorders occurred in those with neutropenia (15). Accordingly, the therapeutic range that covers T. asahii is reasonable in empirical treatment of MBF in patients who develop neutropenia. Current guidelines recommend voriconazole as the preferred therapeutic AFA for treating invasive Trichosporon infection, including fungemia (16, 17), but no randomized controlled trial (RCT) has been conducted to compare voriconazole and other AFAs, including liposomal amphotericin B, for Trichosporon infection. Furthermore, in the above-mentioned systematic review, among patients with Trichosporon infection and hematological disorders, voriconazole-based therapy was associated with more favorable outcomes than therapy with other AFAs (73.6% versus 41.8%, P = 0.016) (15). In our study (Table 4) and a previous study (18), the MICs of voriconazole for Trichosporon were low, whereas the MICs of amphotericin B for Trichosporon were high. Although the MICs of amphotericin B were ≥2 μg/ml (27%) for only 7 of the 26 Candida strains tested for susceptibility, the MICs were ≥2 μg/ml for the 7 T. asahii strains in our study (100%) (P < 0.001). Also, only 1 patient among those who developed T. asahii fungemia received empirical voriconazole treatment (Table 4). That might account for the high 30-day crude mortality rate of patients with T. asahii fungemia (71%). In addition, voriconazole could typically cover C. parapsilosis, which was the second most common causative fungal strain in patients who developed neutropenia (Table 3). Hence, voriconazole might be a suitable appropriate empirical AFA for MBF in patients with neutropenia.

The MICs of azoles, including voriconazole, for C. glabrata (one of the causative fungal strains of MBF) are known to be high (9), and some of the causative fungal strains had high voriconazole MICs (Table 4). Accordingly, combining liposomal amphotericin B and voriconazole might be a more appropriate empirical therapy, especially for neutropenic patients with MBF who also have risk factors for 30-day crude mortality (Table 5). Liposomal amphotericin B might be a reasonable AFA for MBF, especially in nonneutropenic patients, because almost all the causative fungi in nonneutropenic patients were Candida species, which showed wild-type susceptibility to liposomal amphotericin B (Table 4). Furthermore, 16 of the 21 patients in the EMC group received liposomal amphotericin B empirically and EMC improved early mortality significantly (Fig. 1). In our study, empirical voriconazole administration might be difficult in some patients, such as allo-HSCT recipients, because of the possible interactions with other drugs, such as tacrolimus, that are often administered in such patients (19).

This study demonstrated the utility of MALDI-TOF MS for identifying the causative fungal strains of MBF (Table 4). The accuracy of MALDI-TOF MS-based identification in this study is comparable to that in previous reports (20, 21). Thus, MALDI-TOF MS might be useful for providing rapid detection and identification of causative fungal strains of MBF.

Our study has some limitations. First, this was a small retrospective study, not an RCT, conducted among patients with MBF or Trichosporon infection to show the superiority of voriconazole over liposomal amphotericin B or other AFAs. However, conducting RCTs is expected to be challenging. Therefore, larger retrospective studies are needed to determine whether the results of our study are applicable in other clinical settings. Second, AFA susceptibility testing and sequencing-based identification were not performed on all 39 fungal strains, because 4 of the 30 Candida strains were lost. Third, EMC did not improve the 30-day crude mortality rate significantly, although the mortality rate in the EMC group was lower than that of the non-EMC group. The number of patients with MBF was probably insufficient to show the statistical significance. Nevertheless, early initiation of AFA has been reported to improve mortality in patients with invasive fungal infections (22, 23), including breakthrough candidemia (23). Therefore, the efficacy of EMC in reducing the mortality rate is highly considerable. Fourth, Trichosporon might be more common in our institute than in other settings. Recently, cases of Trichosporon fungemia have been reported mainly from countries in Asia, including Japan (24). However, the exact epidemiology of Trichosporon infection in Asia and other regions is yet unknown.

In summary, MBF caused by non-Candida fungal strains should be considered, especially in patients who develop neutropenia. EMC could improve early mortality in patients with MBF. Based on the epidemiology and drug susceptibility profile of MBF, early empirical voriconazole-containing therapy might be suitable for treating MBF in patients with neutropenia, with additional therapeutic coverage for T. asahii.

MATERIALS AND METHODS

We conducted a retrospective analysis of MBF among patients (age ≥ 20 years) with hematological disorders between January 2008 and June 2015 at Toranomon Hospital (Tokyo, Japan; 890 beds) and Toranomon Hospital Kajigaya (Kanagawa, Japan; 300 beds). The medical and microbiological records of these patients were reviewed. This study was approved by the institutional review board (IRB) of Toranomon Hospital. Although the recommended prophylactic dose of micafungin is 50 mg/day (6, 7), a dose of 150 mg/day was administered to some high-risk patients as antimold prophylaxis, in accordance with a clinical trial also approved by the IRB (14).

Definitions.Fungemia was defined as the isolation of any fungal species in ≥1 set of blood culture samples obtained from patients with clinical features. MBF was defined as fungemia occurring in patients receiving intravenous micafungin (≥50 mg/day) for ≥3 days before the first positive blood culture was obtained. This definition is the same as that of breakthrough candidemia (14, 25). A second episode of fungemia occurring in the same patient within 4 weeks of the first episode was considered the same episode (26). Neutropenia was defined as an ANC of ≤500 cells/μl. Administration of systemic steroids or immunosuppressive agents was defined as usage within a period of 90 days before the onset of fungemia. Chronic renal failure was defined as an estimated glomerular filtration rate of <60 ml/min/1.73 m2 over 12 weeks before the onset of fungemia. Septic shock was defined as persistent sepsis-induced hypotension despite adequate resuscitation or cases requiring vasopressor agents (27). Catheter-related fungemia was diagnosed when there was no other apparent source of infection and the fungal strain was isolated from both peripheral blood and catheter tip cultures (14). Empirical AFA was defined as an AFA that was started to treat MBF immediately after discontinuation of micafungin administration. Early micafungin change to other AFAs (EMC) meant that micafungin was switched to empirical AFAs within 48 h after the onset of MBF.

Identification.Blood culture samples were processed using Bactec 9240 (between January 2008 and June 2015) and Bactec FX (between June 2010 and June 2015) systems (Becton Dickinson and Company, Sparks, MD, USA). All breakthrough fungal isolates were recovered on Sabouraud dextrose agar (Nippon Becton Dickinson and Company, Ltd., Japan) at 35°C and identified to the species level by using the Vitek or VITEK2 systems (bioMérieux, Marcy l'Etoile, France) for all fungal strains in the Toranomon Hospital. The internal transcribed spacer (ITS) regions and D1/D2 regions of the rRNA gene of the isolates were sequenced to provide further supportive evidence (28, 29). In addition to these regions, the elongation factor gene (EF-1α) was sequenced for discrimination of Fusarium species (30, 31). The stored strains were also analyzed and identified using the matrix-assisted laser desorption ionization-time of flight mass spectrometry Biotyper preprocessing standard method 1.1 (Bruker Daltonics, Billerica, MA, USA).

Antifungal susceptibility.In vitro susceptibilities of the stored fungal strains obtained from the blood samples to five AFAs (fluconazole, itraconazole, voriconazole, amphotericin B, and micafungin) were determined using the broth microdilution method with a commercial frozen plate for antifungal susceptibility testing (Eiken Chemical Co., Ltd.) that complied with CLSI guideline M27-A3 (32), in accordance with the manufacturer's instructions, and MIC values were interpreted according to the criteria in CLSI testing guideline M27-S4 for yeasts (33), M38-A2 for molds (34), and the ECV for Candida strains (35). C. parapsilosis ATCC 22019 and C. krusei ATCC 6258 were used as quality control isolates.

Evaluating the efficacy of early empirical micafungin change to other antifungal agents.To evaluate the efficacy of EMC in reducing mortality, patients who were treated with EMC (EMC group) were compared with those who were not treated with EMC (non-EMC group). Patients who died within 48 h after the onset of MBF were excluded from this analysis, ensuring that the potential impact of early (≤48-h) micafungin change was properly evaluated. A similar method was used in a previous study on candidemia, which evaluated the outcome of the therapeutic strategy (36). We selected 14-day crude mortality as the primary endpoint, because it was thought to be most reflective of death attributable to MBF. The second outcome was 30-day crude mortality. The same endpoints were used as in the previous study on bloodstream infection for a similar reason (37).

Statistical analysis.Categorical variables were compared using Fisher's exact test. Variables with P values of <0.20 were included in a logistic regression model for multivariate analysis. The 30-day mortality rates were estimated using Kaplan-Meier analysis. Risk factors associated with crude 30-day mortality were analyzed using the log rank test for pre-MBF onset variables with a Cox proportional-hazard regression model for a time-dependent variable (early central venous catheter removal) for univariate analysis. Variables with P values of <0.10 were included in a Cox proportional-hazard regression model with a stepwise method for multivariate analysis. Significance was set at an α of 0.05. All statistical analysis was performed with EZR (Saitama Medical Center, Jichi Medical University, Japan), a graphical user interface for R (The R Foundation for Statistical Computing) (38).

ACKNOWLEDGMENTS

This study was supported by the Research Program on Emerging and Re-emerging Infectious Diseases of the Japan Agency for Medical Research and Development (AMED) under grant number JP17fk0108208.

Identification and drug susceptibility testing was performed by the staff of the microbiology laboratory of Toranomon Hospital and the staff of the Department of Chemotherapy and Mycoses, National Institute of Infectious Diseases.

We report no conflicts of interest. We alone are responsible for the content and writing of this paper.

FOOTNOTES

    • Received 24 October 2017.
    • Returned for modification 21 December 2017.
    • Accepted 25 February 2018.
    • Accepted manuscript posted online 12 March 2018.
  • Supplemental material for this article may be found at https://doi.org/10.1128/AAC.02183-17.

  • Copyright © 2018 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Cornely OA,
    2. Gachot B,
    3. Akan H,
    4. Bassetti M,
    5. Uzun O,
    6. Kibbler C,
    7. Marchetti O,
    8. de Burghgraeve P,
    9. Ramadan S,
    10. Pylkkanen L,
    11. Ameye L,
    12. Paesmans M,
    13. Donnelly JP, EORTC Infectious Diseases Group
    . 2015. Epidemiology and outcome of fungemia in a cancer cohort of the infectious diseases group (IDG) of the European organization for research and treatment of cancer (EORTC 65031). Clin Infect Dis 61:324–331. doi:10.1093/cid/civ293.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Leventakos K,
    2. Lewis RE,
    3. Kontoyiannis DP
    . 2010. Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis 50:405–415. doi:10.1086/649879.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Chitasombat MN,
    2. Kofteridis DP,
    3. Jiang Y,
    4. Tarrand J,
    5. Lewis RE,
    6. Kontoyiannis DP
    . 2012. Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. J Infect 64:68–75. doi:10.1016/j.jinf.2011.11.002.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Matsue K,
    2. Uryu H,
    3. Koseki M,
    4. Asada N,
    5. Takeuchi M
    . 2006. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis 42:753–757. doi:10.1086/500323.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Freifeld AG,
    2. Bow EJ,
    3. Sepkowitz KA,
    4. Boeckh MJ,
    5. Ito JI,
    6. Mullen CA,
    7. Raad II,
    8. Rolston KV,
    9. Young JA,
    10. Wingard JR
    , Infectious Diseases Society of America. 2011. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Disease Society of America. Clin Infect Dis 52:427–431. doi:10.1093/cid/ciq147.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Tacke D,
    2. Buchheidt D,
    3. Karthaus M,
    4. Krause SW,
    5. Maschmeyer G,
    6. Neumann S,
    7. Ostermann H,
    8. Penack O,
    9. Rieger C,
    10. Ruhnke M,
    11. Sandherr M,
    12. Schweer KE,
    13. Ullmann AJ,
    14. Cornely OA
    . 2014. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies. 2014 update of the recommendations of Infectious Diseases Working Party of German Society for Haematology and Oncology. Ann Hematol 93:1449–1456. doi:10.1007/s00277-014-2108-y.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Ullmann AJ,
    2. Akova M,
    3. Herbrecht R,
    4. Viscoli C,
    5. Arendrup MC,
    6. Arikan-Akdagli S,
    7. Bassetti M,
    8. Bille J,
    9. Calandra T,
    10. Castagnola E,
    11. Cornely OA,
    12. Donnelly JP,
    13. Garbino J,
    14. Groll AH,
    15. Hope WW,
    16. Jensen HE,
    17. Kullberg BJ,
    18. Lass-Flörl C,
    19. Lortholary O,
    20. Meersseman W,
    21. Petrikkos G,
    22. Richardson MD,
    23. Roilides E,
    24. Verweij PE,
    25. Cuenca-Estrella M, ESCMID Fungal Infection Study Group
    . 2012. ESCMID guideline for the diagnosis and management of candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 18:53–67. doi:10.1111/1469-0691.12041.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. van Burik JA,
    2. Ratanatharathom V,
    3. Stepan DE,
    4. Miller CB,
    5. Lipton JH,
    6. Vesole DH,
    7. Bunin N,
    8. Wall DA,
    9. Hiemenz JW,
    10. Satoi Y,
    11. Lee JM,
    12. Walsh TJ
    , National Institute of Allergy and Infectious Diseases Mycoses Study Group. 2004. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39:1407–1416. doi:10.1086/422312.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Pappas PG,
    2. Kauffman CA,
    3. Andes DR,
    4. Clancy CJ,
    5. Marr KA,
    6. Ostrosky-Zeichner L,
    7. Reboli AC,
    8. Schuster MG,
    9. Vazquez JA,
    10. Walsh TJ,
    11. Zaoutis TE,
    12. Sobel JD
    . 2016. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 62:e1–e50.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Jung DS,
    2. Farmakiotis D,
    3. Jiang Y,
    4. Tarrand JJ,
    5. Kontoyiannis DP
    . 2015. Uncommon Candida species fungemia among cancer patients, Houston, Texas, USA. Emerg Infect Dis 21:1942–1950. doi:10.3201/eid2111.150404.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Sun HY,
    2. Singh N
    . 2010. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int J Antimicrob Agents 35:211–218. doi:10.1016/j.ijantimicag.2009.09.020.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Nachbaur D,
    2. Angelova O,
    3. Orth-Höller D,
    4. Ditlbacher A,
    5. Lackner M,
    6. Auberger J,
    7. Lass-Flörl C
    . 2015. Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study. Eur J Haematol 94:258–264. doi:10.1111/ejh.12426.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Chan TS,
    2. Gill H,
    3. Hwang YY
    . 2014. Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients. Ann Hematol 93:493–498. doi:10.1007/s00277-013-1882-2.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Kimura M,
    2. Araoka H,
    3. Yamamoto H,
    4. Asano-Mori Y,
    5. Nakamura S,
    6. Yamagoe S,
    7. Ohno H,
    8. Miyazaki Y,
    9. Abe M,
    10. Yuasa M,
    11. Kaji D,
    12. Kageyama K,
    13. Nishida A,
    14. Ishiwata K,
    15. Takagi S,
    16. Yamamoto G,
    17. Uchida N,
    18. Izutsu K,
    19. Wake A,
    20. Taniguchi S,
    21. Yoneyama A
    . 2017. Clinical and microbiological characteristics of breakthrough candidemia in allogeneic hematopoietic stem cell transplant recipients in a Japanese hospital. Antimicrob Agents Chemother 61:e01791–16. doi:10.1128/AAC.01791-16.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. de Almeida Júnior JN,
    2. Hennequin C
    . 2016. Invasive Trichosporon infection: a systematic review on a re-emerging fungal pathogen. Front Microbiol 7:1629.
    OpenUrlCrossRef
  16. 16.↵
    1. Limper AH,
    2. Knox KS,
    3. Sarosi GA,
    4. Ampel NM,
    5. Bennett JE,
    6. Catanzaro A,
    7. Davies SF,
    8. Dismukes WE,
    9. Hage CA,
    10. Marr KA,
    11. Mody CH,
    12. Perfect JR,
    13. Stevens DA
    , American Thoracic Society Fungal Working Group. 2011. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 183:96–128. doi:10.1164/rccm.2008-740ST.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Arendrup MC,
    2. Boekhout T,
    3. Akova M,
    4. Meis JF,
    5. Cornely OA,
    6. Lortholary O
    , European Society of Clinical Microbiology and Infectious Diseases Fungal Infection Study Group, European Confederation of Medical Mycology. 2014. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases. Clin Microbiol Infect 20(Suppl 3):1–4. doi:10.1111/1469-0691.12569.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Chagas-Neto TC,
    2. Chaves GM,
    3. Melo AS,
    4. Colombo AL
    . 2009. Bloodstream infections due to Trichosporon spp.: species distribution, Trichosporon asahii genotypes determined on the basis of ribosomal DNA intergenic spacer 1 sequencing, and antifungal susceptibility testing. J Clin Microbiol 47:1074–1081. doi:10.1128/JCM.01614-08.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Saad AH,
    2. DePestel DD,
    3. Carver PL
    . 2006. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 26:1730–1744. doi:10.1592/phco.26.12.1730.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Kolecka A,
    2. Khayhan K,
    3. Groenewald M,
    4. Theelen B,
    5. Arabatzis M,
    6. Velegraki A,
    7. Kostrzewa M,
    8. Mares M,
    9. Taj-Aldeen SJ,
    10. Boekhout T
    . 2013. Identification of medically relevant species of arthroconidial yeasts by use of matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 51:2491–2500. doi:10.1128/JCM.00470-13.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Stevenson LG,
    2. Drake SK,
    3. Shea YR,
    4. Zelazny AM,
    5. Murray PR
    . 2010. Evaluation of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of clinically important yeast species. J Clin Microbiol 48:3482–3486. doi:10.1128/JCM.00687-09.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Chamilos G,
    2. Lewis RE,
    3. Kontoyiannis DP
    . 2008. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 47:503–509. doi:10.1086/590004.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Sipsas NV,
    2. Lewis RE,
    3. Tarrand J,
    4. Hachem R,
    5. Rolston KV,
    6. Raad II,
    7. Kontoyiannis DP
    . 2009. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 115:4745–4752. doi:10.1002/cncr.24507.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Liao Y,
    2. Lu X,
    3. Yang S,
    4. Luo Y,
    5. Chen Q,
    6. Yang R
    . 2015. Epidemiology and outcome of Trichosporon fungemia: a review of 185 reported cases from 1975 to 2014. Open Forum Infect Dis 2:ofv141. doi:10.1093/ofid/ofv141.
    OpenUrlCrossRef
  25. 25.↵
    1. Gamaletsou MN,
    2. Daikos GL,
    3. Walsh TJ,
    4. Perlin DS,
    5. Ortigosa CJ,
    6. Psaroulaki A,
    7. Pagoni M,
    8. Argyropoulou A,
    9. Nepka M,
    10. Perivolioti E,
    11. Kotsopoulou M,
    12. Perloretzou S,
    13. Marangos M,
    14. Kofteridis D,
    15. Grammatikou M,
    16. Goukos D,
    17. Petrikkos G,
    18. Sipsas NV
    . 2014. Breakthrough candidemia caused by phenotypically susceptible Candida spp. in patients with haematological malignancies dose not correlate with established interpretive breakpoints. Int J Antimicrobial Agents 44:248–255. doi:10.1016/j.ijantimicag.2014.05.015.
    OpenUrlCrossRef
  26. 26.↵
    1. Malani A,
    2. Hmoud J,
    3. Chiu L,
    4. Carver PL,
    5. Bielaczync A,
    6. Kauffman CA
    . 2005. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis 41:975–981. doi:10.1086/432939.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Dellinger RP,
    2. Levy MM,
    3. Rhodes A,
    4. Annane D,
    5. Gerlach H,
    6. Opal SM,
    7. Sevransky JE,
    8. Sprung CL,
    9. Douglas IS,
    10. Jaeschke R,
    11. Osborn TM,
    12. Nunnally ME,
    13. Townsend SR,
    14. Reinhart K,
    15. Kleinpell RM,
    16. Angus DC,
    17. Deutschman CS,
    18. Machado FR,
    19. Rubenfeld GD,
    20. Webb S,
    21. Beale RJ,
    22. Vincent JL,
    23. Moreno R
    , Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. 2013. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41:580–637. doi:10.1097/CCM.0b013e31827e83af.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. White TJ,
    2. Bruns T,
    3. Lee S,
    4. Taylor JW
    . 1990. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics, p 315–322. In Innis MA, Gelfand DH, Sninsky JJ, White TJ (ed), PCR protocols: a guide to methods and applications. Academic Press, Inc, New York, NY.
  29. 29.↵
    1. O'Donnell K
    . 1993. Fusarium and its near relatives, p 225–233. In Reynolds DR, Taylor JW (ed), The fungal holomorph: mitotic, meiotic and pleomorphic speciation in fungal systematics. CAB International, Wallingford, UK.
  30. 30.↵
    1. O'Donnell K,
    2. Kistler HC,
    3. Cigelnik E,
    4. Ploetz RC
    . 1998. Multiple evolutionary origins of the fungus causing Panama disease of banana: concordant evidence from nuclear and mitochondrial gene genealogies. Proc Natl Acad Sci U S A 95:2044–2049.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. O'Donnell K,
    2. Humber RA,
    3. Geiser DM,
    4. Kang S,
    5. Park B,
    6. Robert VA,
    7. Crous PW,
    8. Johnston PR,
    9. Aoki T,
    10. Rooney AP,
    11. Rehner SA
    . 2012. Phylogenetic diversity of insecticolous fusaria inferred from multilocus DNA sequence data and their molecular identification via FUSARIUM-ID and Fusarium MLST. Mycologia 104:427–445. doi:10.3852/11-179.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; 3rd information supplement. Document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
  33. 33.↵
    Clinical and Laboratory Standards Institute. 2012. Reference method for broth dilution antifungal susceptibility testing yeasts; fourth information supplement. Document M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA.
  34. 34.↵
    Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
  35. 35.↵
    1. Pfaller MA,
    2. Diekema DJ
    . 2012. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 50:2846–2856. doi:10.1128/JCM.00937-12.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Fernández-Ruiz M,
    2. Aguado JM,
    3. Almirante B,
    4. Lora-Pablos D,
    5. Padilla B,
    6. Puig-Asensio M,
    7. Montejo M,
    8. García-Rodríguez J,
    9. Pemán J,
    10. Ruiz Pérez de Pipaón M,
    11. Cuenca-Estrella M
    , CANDIPOPProject, GEIH-GEMICOMED (SEIMC), REIPI. 2014. Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis. Clin Infect Dis 58:1413–1421. doi:10.1093/cid/ciu158.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Tamma PD,
    2. Goodman KE,
    3. Harris AD,
    4. Tekle T,
    5. Roberts A,
    6. Taiwo A,
    7. Simner PJ
    . 2017. Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia. Clin Infect Dis 64:257–264. doi:10.1093/cid/ciw741.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Kanda Y
    . 2013. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458. doi:10.1038/bmt.2012.244.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
Micafungin Breakthrough Fungemia in Patients with Hematological Disorders
Muneyoshi Kimura, Hideki Araoka, Hisashi Yamamoto, Shigeki Nakamura, Minoru Nagi, Satoshi Yamagoe, Yoshitsugu Miyazaki, Sho Ogura, Takashi Mitsuki, Mitsuhiro Yuasa, Daisuke Kaji, Kosei Kageyama, Aya Nishida, Yuki Taya, Hiroshi Shimazu, Kazuya Ishiwata, Shinsuke Takagi, Go Yamamoto, Yuki Asano-Mori, Naoyuki Uchida, Atsushi Wake, Shuichi Taniguchi, Akiko Yoneyama
Antimicrobial Agents and Chemotherapy Apr 2018, 62 (5) e02183-17; DOI: 10.1128/AAC.02183-17

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Micafungin Breakthrough Fungemia in Patients with Hematological Disorders
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Micafungin Breakthrough Fungemia in Patients with Hematological Disorders
Muneyoshi Kimura, Hideki Araoka, Hisashi Yamamoto, Shigeki Nakamura, Minoru Nagi, Satoshi Yamagoe, Yoshitsugu Miyazaki, Sho Ogura, Takashi Mitsuki, Mitsuhiro Yuasa, Daisuke Kaji, Kosei Kageyama, Aya Nishida, Yuki Taya, Hiroshi Shimazu, Kazuya Ishiwata, Shinsuke Takagi, Go Yamamoto, Yuki Asano-Mori, Naoyuki Uchida, Atsushi Wake, Shuichi Taniguchi, Akiko Yoneyama
Antimicrobial Agents and Chemotherapy Apr 2018, 62 (5) e02183-17; DOI: 10.1128/AAC.02183-17
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

micafungin
breakthrough fungemia
echinocandin
Trichosporon
voriconazole
Trichosporon asahii
breakthrough candidemia
echinocandin breakthrough
matrix-assisted laser desorption ionization–time of flight mass spectrometry

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596